FUS (Fused in Sarcoma) Protein

Pathway Diagram

flowchart TD
    FUS["FUS"]
    RNA["RNA Processing"]
    FUS -->|"regulates"| RNA
    style FUS fill:#4fc3f7,stroke:#333,color:#000
    style RNA fill:#81c784,stroke:#333,color:#000

Introduction

Fus (Fused In Sarcoma) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.^{1Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma1993 · Nature · PMID 8453667Open reference}

Overview

FUS (Fused in Sarcoma), also known as TLS (Translocated in Liposarcoma), is a multifunctional RNA-binding protein encoded by the FUS gene on chromosome 16p11.2. It belongs to the FET family of proteins (FUS, EWSR1, TAF15) and plays essential roles in DNA repair, transcription regulation, RNA splicing, and RNA transport. FUS was first identified as part of a chromosomal translocation in human myxoid liposarcoma,^{1Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma1993 · Nature · PMID 8453667Open reference} but gained prominence in neurodegeneration research when mutations in FUS were identified as causative for familial ALS^{2Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis2009 · Science · PMID 19251628Open reference3Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 62009 · Science · PMID 19251627Open reference} and FTD.

FUS is a 526-amino acid protein that is predominantly nuclear in healthy neurons but mislocalizes to the cytoplasm in disease states, where it forms pathological aggregates through aberrant liquid-liquid phase separation (LLPS). Mutations in FUS account for approximately 4–5% of familial ALS cases and are particularly associated with aggressive juvenile-onset forms of the disease.^{4TAR DNA-binding protein 43 in amyotrophic lateral sclerosis and frontotemporal dementia2010 · Lancet Neurol · PMID 20644738Open reference} FUS pathology is also found in a subset of FTD cases lacking tau or TDP-43 inclusions, classified as FTLD-FUS.^{5A new subtype of frontotemporal lobar degeneration with FUS pathology2009 · Brain · PMID 19628797Open reference}

Protein Structure and Domains

FUS is a 526-amino acid protein with a modular domain architecture that is asymmetrically divided into a low complexity domain (LCD) and an RNA-binding domain (RBD):^{6Cell-free formation of RNA granules: low complexity sequence domains form dynamic fibers within hydrogels2012 · Cell · PMID 22579281Open reference}

• QGSY-rich prion-like domain (PrLD, residues 1–165): An intrinsically disordered N-terminal region enriched in glutamine, glycine, serine, and tyrosine residues. This domain mediates liquid-liquid phase separation and is critical for FUS self-assembly into biomolecular condensates. Post-translational modifications including phosphorylation regulate its phase behavior.^{7Phosphorylation of the FUS low-complexity domain by DNA-PK regulates its phase separation and pathogenic aggregation2017 · Nat Neurosci · PMID 29068722Open reference}

• RGG1 domain (residues 165–267): The first arginine-glycine-glycine repeat region, which contributes to RNA binding and phase separation through electrostatic interactions.

• RNA Recognition Motif (RRM, residues 285–370): A canonical RNA-binding domain that recognizes specific RNA motifs including GGUG and GUGGU sequences.^{8Identification of an RNA binding specificity for the FUS/TLS protein2001 · J Biol Chem · PMID 11524676Open reference}

• RGG2 domain (residues 370–422): The second RGG repeat region.

• Zinc finger domain (ZnF, residues 422–453): A C2/C2-type zinc finger that binds both RNA and DNA and contributes to nucleic acid binding specificity.

• RGG3 domain (residues 453–501): The third RGG repeat region.

• Nuclear Localization Signal (NLS, residues 510–526): A PY-NLS at the C-terminus recognized by the nuclear import receptor Transportin-1 (TNPO1/Karyopherin-β2). Most ALS-causing mutations cluster in or near this domain, disrupting nuclear import.^{9ALS-associated fused in sarcoma (FUS) mutations disrupt Transportin-mediated nuclear import2010 · EMBO J · PMID 20386736Open reference}

Physiological Functions

RNA Metabolism

FUS is one of the most abundant RNA-binding proteins in the nucleus and participates in virtually every step of RNA metabolism:^{1Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma1993 · Nature · PMID 8453667Open reference}0

• Transcription: FUS interacts with RNA polymerase II and the TFIID complex to regulate gene expression. It binds to single-stranded DNA at gene promoters and can function as both a transcriptional activator and repressor.

• Pre-mRNA Splicing: FUS associates with the spliceosome and regulates alternative splicing of hundreds of mRNAs. Loss of FUS leads to widespread splicing alterations, particularly affecting genes involved in neuronal function and synaptic signaling.

• mRNA Transport: FUS is a component of neuronal RNA granules and facilitates mRNA transport along axons and dendrites, delivering transcripts to sites of local translation at synapses and growth cones.

• microRNA Processing: FUS promotes Drosha-mediated processing of specific microRNA precursors, linking it to post-transcriptional gene regulation.^{1Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma1993 · Nature · PMID 8453667Open reference}1

DNA Damage Response

FUS rapidly localizes to sites of DNA damage, where it facilitates the DNA damage response (DDR).^{1Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma1993 · Nature · PMID 8453667Open reference}2 Through its interaction with poly(ADP-ribose) (PAR), FUS is recruited to DNA double-strand breaks within seconds, preceding other repair factors. FUS facilitates both homologous recombination and non-homologous end joining repair pathways. Impaired DNA damage repair has been demonstrated in cortical neurons from ALS patients carrying FUS mutations, linking FUS dysfunction to genomic instability and neurodegeneration.^{1Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma1993 · Nature · PMID 8453667Open reference}3

Stress Granule Dynamics

Under cellular stress, FUS is recruited to stress granules (SGs)—cytoplasmic ribonucleoprotein assemblies that temporarily halt translation of non-essential mRNAs. FUS contributes to SG assembly through its prion-like domain.^{1Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma1993 · Nature · PMID 8453667Open reference}4 Pathological mutations promote persistent SG formation and impair SG disassembly, potentially serving as nucleation sites for irreversible FUS aggregation.^{1Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma1993 · Nature · PMID 8453667Open reference}5

Liquid-Liquid Phase Separation

FUS has become a paradigmatic protein for studying biomolecular condensate formation through liquid-liquid phase separation (LLPS):^{1Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma1993 · Nature · PMID 8453667Open reference}6

• Normal LLPS: FUS undergoes reversible phase separation to form dynamic liquid-like droplets in the nucleus, where it participates in transcription hubs, DNA repair foci, and paraspeckles. The prion-like LCD drives droplet formation, while the RBD modulates condensate properties through RNA engagement.

• Aberrant Phase Transitions: Under pathological conditions—including disease-associated mutations, elevated protein concentration, or prolonged stress—FUS droplets undergo maturation from liquid to gel to solid states, forming amyloid-like fibrils.^{1Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma1993 · Nature · PMID 8453667Open reference}7 This irreversible “aging” of condensates is a key step in pathological aggregation.

• Regulation: FUS phase behavior is modulated by post-translational modifications (phosphorylation of serine residues in the LCD by DNA-PK reduces LLPS), RNA binding (RNA opposes aggregation at physiological concentrations), and chaperone activity (DNAJB6 can maintain FUS in a loose gel-like state, preventing fibrilization).^{1Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma1993 · Nature · PMID 8453667Open reference}8

Role in Disease

ALS (Amyotrophic Lateral Sclerosis)

Mutations in FUS cause approximately 4–5% of familial ALS and ~1% of sporadic ALS cases. Over 50 disease-associated mutations have been identified, with the majority clustering in the C-terminal NLS domain:^{1Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma1993 · Nature · PMID 8453667Open reference}9

• P525L: Consistently associated with severe juvenile-onset ALS (age of onset often <25 years), with rapid disease progression and a mean survival of ~12 months. Often occurs de novo.^{2Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis2009 · Science · PMID 19251628Open reference}0

• R521C/R521H/R521G: The most common FUS mutations in ALS, associated with adult-onset disease with a more variable course. R521C patients show tangle-like neuronal cytoplasmic inclusions.

• H517Q: Associated with adult-onset ALS with a moderately aggressive course.

FUS-ALS shows two distinct pathological patterns correlating with disease severity: (1) early-onset aggressive disease with basophilic inclusions and round FUS-immunoreactive neuronal cytoplasmic inclusions (P525L, R522G), and (2) later-onset disease with tangle-like inclusions and frequent glial cytoplasmic inclusions (R521C).^{2Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis2009 · Science · PMID 19251628Open reference}1

Frontotemporal Dementia (FTD)

FUS pathology defines a subset of FTD known as FTLD-FUS, which accounts for approximately 9% of all FTLD cases with ubiquitin-positive inclusions.^{2Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis2009 · Science · PMID 19251628Open reference}2 Three subtypes are recognized:

1. Atypical FTLD-U (aFTLD-U): Characterized by neuronal intranuclear inclusions (NIIs) containing FUS; typically presents with behavioral variant FTD in young patients.

2. Neuronal Intermediate Filament Inclusion Disease (NIFID): Features inclusions containing FUS along with intermediate filaments.

3. Basophilic Inclusion Body Disease (BIBD): Characterized by basophilic inclusions that are FUS-immunoreactive.

Notably, unlike FUS-ALS, FTLD-FUS cases rarely harbor FUS mutations, suggesting a different pathogenic mechanism involving wild-type FUS aggregation.^{2Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis2009 · Science · PMID 19251628Open reference}3

Pathogenic Mechanisms

• Cytoplasmic Mislocalization: ALS-causing mutations in the NLS impair Transportin-1-mediated nuclear import, leading to cytoplasmic accumulation where FUS forms toxic aggregates.^{2Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis2009 · Science · PMID 19251628Open reference}4

• Loss of Nuclear Function: Nuclear depletion of FUS causes widespread RNA processing defects, including mis-splicing of genes essential for neuronal survival.

• Gain of Cytoplasmic Toxicity: Mislocalized FUS sequesters other RNA-binding proteins and mRNAs into aggregates, disrupting local translation at synapses and axonal transport.

• Prion-Like Propagation: FUS aggregates can seed misfolding of native FUS protein, potentially explaining the progressive spread of pathology observed in ALS/FTD.^{2Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis2009 · Science · PMID 19251628Open reference}5

Therapeutic Approaches

Antisense Oligonucleotides (ASOs)

ASOs targeting FUS mRNA to reduce FUS protein levels have shown promise in preclinical models. Intrathecal delivery of FUS-targeting ASOs reversed motor neuron degeneration in mouse models.^{2Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis2009 · Science · PMID 19251628Open reference}6 Jacifusen (ION363), an ASO targeting FUS, was the first personalized ASO therapy administered to an ALS patient under compassionate use.^{2Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis2009 · Science · PMID 19251628Open reference}7

Chaperone-Based Strategies

Molecular chaperones that prevent aberrant FUS phase transitions represent a promising therapeutic avenue. DNAJB6 promotes non-toxic FUS condensate gelation and inhibits neurotoxicity.^{2Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis2009 · Science · PMID 19251628Open reference}8 Heat shock proteins and the ubiquitin-proteasome system are also being explored as strategies to clear FUS aggregates.

Small Molecule Modulators

Compounds that stabilize FUS in its liquid-like state and prevent aberrant solid-state transitions are under investigation. Targeting the Transportin-1–FUS interaction to restore nuclear import is another active area of drug discovery.

Relationship to Other Proteins

FUS shares structural and functional similarities with TDP-43, another RNA-binding protein implicated in ALS and FTD. Both proteins contain prion-like domains and undergo pathological phase transitions. However, FUS and TDP-43 pathology are generally mutually exclusive in patient tissues, suggesting parallel but distinct disease pathways.^{2Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis2009 · Science · PMID 19251628Open reference}9

FUS also interacts with SOD1, another ALS-associated protein. Co-aggregation of FUS with other RNA-binding proteins, including hnRNPA1, hnRNPA2/B1, and EWSR1, has been observed in disease models, indicating that FUS toxicity may extend beyond the protein itself to a broader disruption of RNA metabolism.^{3Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 62009 · Science · PMID 19251627Open reference}0

Key Findings

• FUS mutations are the second most common cause of familial ALS after C9orf72 repeat expansions and SOD1 mutations.

• FUS is the prototypical protein for studying pathological phase separation in neurodegeneration.

• The P525L mutation causes one of the most aggressive forms of ALS known, with juvenile onset and rapid progression.

• ASO therapy targeting FUS has entered human clinical use under compassionate access protocols.

• FUS-FTD and FUS-ALS appear to involve distinct pathogenic mechanisms despite involving the same protein.

• FUS plays crucial roles in DNA damage repair, linking neurodegeneration to genomic instability.

See Also

• FUS Protein — Protein encoded by FUS gene

• ALS — Motor neuron disease linked to FUS mutations

• FTD — Frontotemporal dementia with FUS pathology

• TDP-43 — Related RNA-binding protein in ALS

• Stress Granules — Structures involving FUS

• DNA Damage Response — FUS role in genome stability